The Australian government is urging healthcare professionals to exercise caution when using AI-powered medical scribing tools, as regulators examine whether stronger safeguards are needed around one of healthcare’s fastest-growing technologies, according to a report by The Guardian.
AI scribes have rapidly gained popularity by recording, transcribing, and summarising doctor-patient conversations into clinical notes, reducing the administrative burden on healthcare workers. However, government officials now warn that the technology’s rapid adoption has outpaced oversight, raising questions around patient privacy, informed consent, and the accuracy of medical records.
Australia’s AI scribe boom is now attracting regulatory scrutiny
According to documents obtained by The Guardian Australia through freedom of information requests, Australia’s federal health department has identified several risks associated with AI scribing tools. Briefing papers prepared for Senate Estimates in February 2026 describe the technology as having “little oversight” and note that some AI scribes are marketed as operating outside existing medical device regulations despite being used in clinical settings.
The concerns come as adoption continues to surge. An online survey conducted by the Royal Australian College of General Practitioners (RACGP) found that the proportion of Australian doctors using AI scribes nearly doubled from 22 percent in August 2024 to 40 percent by November 2025. Technology providers also claim their platforms have processed hundreds of millions of consultations globally over the past 18 months.
While the health department acknowledges that AI scribes could improve clinician productivity and help reduce burnout, it also warns that these tools inherit many of the same limitations as large language models. Errors in transcription or summarisation could affect patient safety, clinical accountability, and the quality of information stored in Australia’s digital health infrastructure.
Privacy has emerged as another major concern
Officials found that some providers promote their products as privacy compliant while offering limited transparency about how patient information is processed. In some cases, healthcare providers may not even realise patient data is being transmitted to cloud servers outside Australia, potentially exposing sensitive medical information to additional risks.
The department also questioned marketing claims suggesting AI scribes can increase doctors’ revenue by around 30 percent without extending working hours or seeing more patients. Officials noted that such claims could have broader implications for Australia’s publicly funded Medicare system if higher billing becomes a primary incentive for adoption.
Patient consent is another area drawing attention. The government found significant variation in how clinics obtain permission before recording consultations, arguing that meaningful informed consent requires patients to understand both the benefits and limitations of AI-assisted documentation. Consumer groups have similarly reported instances where patients were told they would need to find another healthcare provider if they declined to have AI scribes used during appointments.
The regulatory landscape remains fragmented. Oversight is currently shared between the Therapeutic Goods Administration (TGA), the Australian Health Practitioner Regulation Agency (Ahpra), and the Office of the Australian Information Commissioner. The TGA is currently reviewing whether AI scribes should be formally classified as medical devices, a decision that could bring many platforms under stricter regulatory oversight. A report is expected in the coming months.
The debate reflects a broader challenge facing healthcare systems worldwide. AI tools are increasingly capable of reducing paperwork and giving doctors more time with patients, but governments are also being forced to balance those efficiency gains against the need to protect patient privacy, ensure clinical accuracy, and establish clear accountability when artificial intelligence becomes part of medical decision-making.
